Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.57 |
| ▸ | CDK2 | P24941 | 10/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.50 |
| ▸ | GPR39 | O43194 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953291 | 0.89 | GSK3B (0.74) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13146269 | 0.81 | CDK2 (0.79) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13304802 | 0.80 | GSK3B (0.54) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL14050900 | 0.80 | GSK3B (0.61) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305376 | 0.80 | CDK2 (0.61) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305188 | 0.80 | GSK3B (0.63) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13304910 | 0.80 | GSK3B (0.60) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13304918 | 0.80 | GSK3B (0.62) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305403 | 0.79 | GSK3B (0.59) | GSK3BCDK2CCNA2CCNA1GPR39 | |
| SCHEMBL13305687 | 0.78 | GSK3B (0.57) | GSK3BCDK2CCNA2CCNA1GPR39 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |